Latest news
Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research
Debiopharm to Reveal Insights from their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at The 2025 AACR Conference in…
Debiopharm mutualise son infrastructure de bornes de recharges pour les taxis électriques ou hybrides de Lausanne
MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s…
Genialis advances biomarker discovery to reduce risk in cancer drug development targeting DNA damage response pathways
Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea
Vulgaroo remporte le 9e Challenge qualité de vie du patient avec un prix de 25’000 francs suisse
CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections